<DOC>
	<DOC>NCT01577381</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.</brief_summary>
	<brief_title>Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration</brief_title>
	<detailed_description>The trial was terminated early on April 12, 2013 due to an organizational decision, which was not based on safety or efficacy concerns. Subjects who were already enrolled into the study were followed.</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Men and women between the ages of 60 and 90 years. Diagnosis of a geographic atrophy (GA) secondary to dry AgeRelated Macular Degeneration. Best Corrected Visual Acuity (BCVA) of 20/80 or better in the study eye Evidence of ocular disease other than geographic atrophy (GA) secondary to dry AgeRelated Macular Degeneration in the study eye. History or diagnosis of exudative (wet) AgeRelated Macular Degeneration, with subretinal or choroidal neovascular lesions in the study eye. Presence of disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, central nervous, immune, or gastrointestinal system</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>Advanced Dry Age-Related Macular Degeneration</keyword>
	<keyword>Geographic Atrophy</keyword>
	<keyword>RN6G</keyword>
</DOC>